I described it in an earlier article as: Qelbree (viloxazine extended-release capsules) is Supernus' latest and greatest product. It was initially approved in 04/2021 to treat ADHD in pediatric ...

Glazer has been diagnosed with anxiety, depression, ADHD and bipolar disorder. His mental health playbook includes frequent ...

They call it masking. That’s when someone with ADHD or autism tries to act how you expect them to, but not in a way that makes sense for them. They tell us it can be exhausting.

This book is just one of two books a local mom and son duo has published dedicated to spotlighting parent and child ...

(Women are being diagnosed with ADHD at unprecedented rates. Here’s why.) But correlation doesn't necessarily equal causation, and there are limitations related to the age, sample size ...

Supernus (SUPN) Pharmaceuticals announced that ... Qelbree is approved for use in patients ages 6 years and older with ADHD. Published first on TheFly – the ultimate source for real-time ...

Jessica Booth is a New York-based freelance writer who regularly writes about health, wellness, parenting, food, travel, beauty and more for a variety of publications. She currently writes for ...

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition that is typically diagnosed during childhood. ADHD can also be diagnosed in ...

Qelbree® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals ...